Home > Boards > US Listed > Biotechs >

Cellular Biomedicine Group, Inc. (CBMG)

Add CBMG Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 1/30/2021 6:48:35 PM - Followers: 37 - Board type: Free - Posts Today: 0

Cellular Biomedicine Group (NASDAQ: CBMG)
530 University Avenue
Suite 17
Palo Alto, CA
94301, USA
Phone: +1 650 566 5064
Email: info@CellBioMedGroup.com
Homepage: http://www.cellbiomedgroup.com/


Cellular Biomedicine Group, Inc. is a development stage biomedicine firm engaged in the development of effective treatments for degenerative and cancerous diseases.

Cellular Biomedicine Group (NASDAQ: CBMG) is a biomedicine firm engaged in the development of effective treatments for degenerative and cancerous diseases utilizing proprietary cell therapy technologies. We are the result of the acquisition, transfer, commercialization and advancement of thirty years of research and human treatment experience in cellular medicine. Our cellular research and development comes from collaboration among scientists and doctors from the US, Europe and China.



Our primary target market is Greater China. Our first two therapy candidates are currently used to treat patients in research studies conducted in China. We are also engaged in a number of pre-clinical studies for other product or therapy candidates, which we believe have the potential to become safe and effective treatment options for a variety of degenerative and debilitating conditions. We believe that the results of our research studies will support expanded preclinical and clinical trials with a larger population of patients, which we expect to carry out through authorized treatment centers throughout Greater China. With the recent acquisition of AG, we added technical services revenue comprised of T Cells Receptor (“TCR”) clonality analysis technology and T Central Memory Cell (“Tcm”) and Dendritic Cell (“DC”) preparation methodologies.

Knee Osteoarthritis (KOA)

Indication: Knee Osteoarthritis (KOA)

Technology Platform: Human Adipose-Derived Mesenchymal Progenitor Cells (haMPC)

Trial Phase: Clinical Trial Phase IIb, all patients completed treatment as of August 2014

Interim results from phase IIb clinical trial for KOA: klick here


Osteoarthritis is a degenerative disease of the joints. KOA is one of the most common types of osteoarthritis. Pathological manifestation of osteoarthritis is primarily local inflammation caused by immune response and subsequent damage of joints. Restoration of immune response and joint tissues are the objective of therapies.

According to International Journal of Rheumatic Diseases, 2011, 53% of KOA patients will degenerate to the point of disability. Conventional treatment usually involves invasive surgery with painful recovery and physical therapy. As drug-based methods of management are ineffective, the same journal estimates that some 1.5 million patients with this disability will degenerate to the point of requiring artificial joint replacement surgery every year. However, only 40,000 patients will actually be able to undergo replacement surgery, leaving the majority of patients to suffer from a life-long disability due to lack of effective treatment.

About haMPCs

haMPCs are currently being considered as a new and effective treatment for osteoarthritis, with a huge potential market. Osteoarthritis is one of the ten most disabling diseases in developed countries. Worldwide estimates are that 9.6% of men and 18.0% of women aged over 60 years have symptomatic osteoarthritis. It is estimated that the global OA therapeutics market was worth $4.4 billion in 2010 and is forecast to grow at a compound annual growth rate (“CAGR”) of 3.8% to reach $5.9 billion by 2018.

In order to bring haMPC-based KOA therapy to market, our market strategy is to: (a) establish regional laboratories that comply with cGMP standards in Shanghai and Beijing that meet Chinese regulatory approval; and (b) file joint applications with Class AAA hospitals (own commentary: press release from 09.02.2015 (klick here): We look forward to working with PLAGH as a long-term partner as we evaluate paths to commercialization,” commented Dr. William (Wei) Cao, Chief Executive Officer of Cellular Biomedicine Group.) to use haMPCs to treat KOA in a clinical trial setting.


Our KOA therapy is not surgically invasive – it uses a small amount (30ml) of adipose tissue obtained via liposuction from the patient, which is cultured and re-injected into the patient. The injections are designed to induce the body’s secretion of growth factors promoting immune response and regulation, and regrowth of cartilage. The down-regulation of the patient’s immune response is aimed at reducing and controlling inflammation which is a central cause of KOA.

We believe our proprietary method, subsequent haMPC proliferation and processing know-how will enable haMPC therapy to be a low cost and relatively safe and effective treatment for KOA. Additionally, banked haMPCs can continue to be stored for additional use in the future.

More products:   klick here


Annual report 31.03.2015:

In March 2015, the Company initiated a financing transaction pursuant to which it would sell up to 526,316 shares of the Company’s common stock, to selected investors at $38 per share, for total gross proceeds of approximately $20,000,000. The Shares were sold pursuant to separate subscription agreements between the Company and each Investor. Up to the issuance of the financial statements, $20,000,000 (unaudited) were received from investors.

Source: http://www.cellbiomedgroup.com/


Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CBMG News: Termination of Registration of a Class of Security Under Section 12(g) (15-12g) 03/03/2021 02:40:58 PM
CBMG News: Notice of Effectiveness (effect) 02/26/2021 06:14:37 AM
CBMG News: Notice of Effectiveness (effect) 02/26/2021 06:12:06 AM
CBMG News: Notice of Effectiveness (effect) 02/26/2021 06:11:40 AM
CBMG News: Amended Statement of Beneficial Ownership (sc 13d/a) 02/22/2021 06:02:28 AM
#2750   Not sure why they bothered, with this telephone richrichrich 01/30/21 06:48:35 PM
#2749   Was hoping for more fan fair after the Djk0689 01/08/21 02:46:21 PM
#2748   CBMG. There’s a big poker game going on Aitkenresearch 08/12/20 04:38:03 PM
#2747   Guess it's time to say bye-bye, to Tony richrichrich 08/12/20 04:33:26 PM
#2746   Cbmg did mention the possible partnership with China Aitkenresearch 04/22/20 07:27:32 AM
#2745   No. I’m not happy with 19.50. I’ve been Aitkenresearch 11/21/19 09:33:36 PM
#2744   With the alljoin soon to be marketed and drugmanrx 11/15/19 11:09:24 PM
#2743   Btw, I used to be able to read richrichrich 11/15/19 10:49:08 PM
#2742   I guess he's entitled to do whatever he richrichrich 11/15/19 10:27:04 PM
#2741   Is it me or isn't there a conflict drugmanrx 11/14/19 09:15:17 AM
#2740   Going private? Never have I seen such a richrichrich 11/11/19 04:35:45 PM
#2739   Eastbridge drugmanrx 09/16/19 07:47:11 PM
#2738   What penny stock was it Minitruckin 09/16/19 07:17:12 PM
#2737   For a company, that previously was a penny richrichrich 04/23/19 07:15:07 PM
#2736   Since this board is inactive I will post surfer44 03/30/18 01:14:06 PM
#2735   Big day for Cbmg to 18.00. I think Aitkenresearch 01/05/18 04:33:08 PM
#2733   That 45% down day was good advertising. surfer44 05/15/17 11:19:43 AM
#2732   Nice returning to form Tdash 05/15/17 10:28:12 AM
#2731   Coming back nicely, due to the new trial richrichrich 05/15/17 10:02:25 AM
#2730   Interesting articles.... richrichrich 05/13/17 04:36:49 PM
#2729   Or maybe this. Coincident they both happen on drugmanrx 05/13/17 01:47:42 PM
#2728   The only thing I could come up with drugmanrx 05/13/17 01:24:09 PM
#2727   The only thing I can speculate is that richrichrich 05/13/17 09:39:58 AM
#2726   I can't find anything that might have caused drugmanrx 05/12/17 06:05:06 PM
#2725   Jeez....45% down, in a day..... richrichrich 05/12/17 05:48:49 PM
#2724   Me too. I still hold on to my richrichrich 05/03/17 09:02:00 AM
#2723   I'm a shareholder. Have been since they were surfer44 05/02/17 09:59:21 PM
#2722   So. The Kwokster(director), buys a million dollars worth richrichrich 05/02/17 09:11:32 PM
#2721   Ah yes.... richrichrich 06/22/16 02:22:11 PM
#2720   market may know something bad? It's year begin, konshe 01/15/16 11:27:56 AM
#2719   $CBMG recent news/filings stocktrademan 11/14/15 12:02:21 PM
#2718   $CBMG recent news/filings stocktrademan 07/02/15 01:03:42 PM
#2717   surfer - thanks. This in spite of catty 06/28/15 08:15:00 AM
#2716   It's going to the Russell 3000 surfer44 06/27/15 08:20:36 PM
#2715   Why the rise especially in a down market? catty 06/27/15 04:02:00 PM
#2714   Anyone know if we're exhibiting at ASCO in Chicago? catty 06/01/15 10:05:03 AM
#2713   Keep tryin...Hagens/Berman...Lost cause....LOL richrichrich 05/26/15 08:53:39 PM
#2712   $CBMG recent news/filings stocktrademan 04/15/15 10:15:35 AM
#2711   Something smelled fishy and somebody knew something bearish edge 04/07/15 10:07:44 PM
#2710   What interesting this come out day they did drugmanrx 04/07/15 08:37:32 PM
#2709   Unbelievable. Several other lawyer firms, have jumped on richrichrich 04/07/15 08:32:51 PM
#2708   From the beginning of my time in the mythical_phenix 04/07/15 07:10:28 PM
#2707   Well, lets hope most of these allegations are unfounded.... richrichrich 04/07/15 03:56:40 PM
#2706   Yes it is, I bailed on the bounce edge 04/06/15 02:04:33 PM
#2705   Heavily shorted today with record high volume apapado2013 04/06/15 12:36:21 PM
#2704   Another china Baidu in the making here? Waiting edge 04/05/15 07:33:40 PM
#2703   I didn't have any cash to add on surfer44 04/02/15 03:24:47 PM
#2702   Long now @ 35.30, may God help us all....................... edge 04/02/15 03:20:06 PM
#2701   This one is now on my watch very edge 04/02/15 02:33:23 PM
#2700   Yes, it's a buy-on-the-dip stock. surfer44 03/31/15 01:23:26 PM
Consent Preferences